Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis

Key facts

Sponsor

All India Institute of Medical Sciences

Principal Investigator

Surendra K Sharma, MD. Ph.D

All India Institute of Medical Sciences

Intervention

INH, Rifampicin, Ethambutol and Pyrazinamide(drug)

Enrollment

150 enrolled

Eligibility

18-60 years · All sexes

Timeline

2006 – 2011

Study locations (1)

• All India Institute of Medcial Sciences, New Delhi, New Delhi, India

Collaborators

Ministry of Health & Family Welfare, India

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary genito-urinary tuberculosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT05917210
  Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
  Yale University
• RECRUITINGNCT07312266
  Questioning the Epidemiology of Asymptomatic TB
  Barcelona Institute for Global Health
• RECRUITINGNANCT05842161
  South Africa Smoking Cessation and Engagement in HIV/TB Care Care
  Massachusetts General Hospital
• RECRUITINGPHASE3NCT05575518
  A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
  Stellah Mpagama
• ACTIVE NOT RECRUITINGPHASE4NCT05118490
  Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
  The Aurum Institute NPC
• RECRUITINGNANCT05342064
  Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
  Baylor College of Medicine

See all trials for Primary genito-urinary tuberculosis →